Overview

Impact of Anti-static Chamber/Mask

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
To compare lung delivery of fluticasone propionate delivered by HFA-pMDI, using a conventional polycarbonate of anti-static chamber/mask in a randomized crossover design in 1-6 year old children. Hypothesis: Anti-static chamber/mask would increase the amount of inhaled corticosteroid delivered to young children who passively inhale and cannot breath hold.
Phase:
Phase 4
Details
Lead Sponsor:
University of Florida
Collaborator:
GlaxoSmithKline
Treatments:
Fluticasone